By Professor Martin Gallagher

Preprints

Neuen B; Jun M; Wick J; Kotwal S; Badve S; Jardine M; Gallagher M; Chalmers J; Nallaiah K; Perkovic V; Peiris D; Rodgers A; Woodward M; Ronksley P, 2023, Estimating the population-level kidney benefits of improved uptake of SGLT2 inhibitors in patients with chronic kidney disease in Australian primary care, http://dx.doi.org/10.1101/2023.06.26.23291881

Barbieri S; Kemp J; Perez-Concha O; Kotwal S; Gallagher M; Ritchie A; Jorm L, 2020, Benchmarking Deep Learning Architectures for Predicting Readmission to the ICU and Describing Patients-at-Risk, http://dx.doi.org/10.48550/arxiv.1905.08547

Foote C; Hockham C; Sukkar L; Campain A; Kang A; Young T; Cass A; Chow CK; Comino E; Gallagher M; Jan S; Knight J; Liu B; McNamara M; Peiris D; Pollock C; Sullivan D; Wong G; Zoungas S; Rogers K; Jun M; Jardine M, EXamining ouTcomEs in chroNic Disease in the 45 and Up Study (the EXTEND45 Study): Protocol for an Australian Linked Cohort Study (Preprint), http://dx.doi.org/10.2196/preprints.15646

Billot L; Wong MG; De Vriese A; Collister D; Flahault A; Mushahar L; Ramachandran R; Skhiri H; Shaman A; Menne J; Gallagher M, Statistical Analysis Plan for the Treatment of Cardiovascular disease with low dose Rivaroxaban in Advanced CKD (TRACK) trial, http://dx.doi.org/10.1101/2025.11.25.25340065

Jun M; Wick J; Neuen BL; Kotwal S; Badve SV; Woodward M; Chalmers J; Peiris D; Rodgers A; Nallaiah K; Jardine MJ; Perkovic V; Gallagher M; Ronksley PE, The prevalence of chronic kidney disease in Australian primary care: analysis of a national general practice dataset, http://dx.doi.org/10.1101/2023.06.18.23290762

Back to profile page